{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:08:08Z","timestamp":1774969688409,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Il\u00eddio Pinho professorship and Institute of Biomedicine of Aveiro","award":["UID\/BIM\/04501\/2013"],"award-info":[{"award-number":["UID\/BIM\/04501\/2013"]}]},{"name":"University of Aveiro, Portugal"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.cca.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T18:01:58Z","timestamp":1549389718000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Comparison between amyloid-PET and CSF amyloid-\u03b2 biomarkers in a clinical cohort with memory deficits"],"prefix":"10.1016","volume":"492","author":[{"given":"Caroline","family":"Bouter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9326-8193","authenticated-orcid":false,"given":"Jonathan","family":"Vogelgsang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5330","authenticated-orcid":false,"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2015","key":"10.1016\/j.cca.2019.02.005_bb0005","first-page":"459","article-title":"Alzheimer's disease facts and figures","volume":"11","author":"A. Alzheimers Association","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cca.2019.02.005_bb0010","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","article-title":"Biomarker modeling of Alzheimer's disease","volume":"80","author":"Jack","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.cca.2019.02.005_bb0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cca.2019.02.005_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"Contributors, NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cca.2019.02.005_bb0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.mcna.2013.01.001","article-title":"International work group criteria for the diagnosis of Alzheimer disease","volume":"97","author":"Cummings","year":"2013","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.cca.2019.02.005_bb0035","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer's disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.cca.2019.02.005_bb0040","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased \u03b2-amyloid 1-42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2019.02.005_bb0045","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","article-title":"Amyloid beta peptide ratio 42\/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load","volume":"101","author":"Wiltfang","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2019.02.005_bb0050","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-170793","article-title":"Reproducibility of Alzheimer's disease cerebrospinal fluid-biomarker measurements under clinical routine conditions","volume":"62","author":"Vogelgsang","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2019.02.005_bb0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"tau Protein in Cerebrospinal Fluid","volume":"26","author":"Blennow","year":"1995","journal-title":"Molecular and Chimical Neuropathology"},{"key":"10.1016\/j.cca.2019.02.005_bb0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.semnuclmed.2011.03.001","article-title":"Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent","volume":"41","author":"Lister-James","year":"2011","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.cca.2019.02.005_bb0065","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.cca.2019.02.005_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/brain\/awq349","article-title":"Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer's disease","volume":"134","author":"Kadir","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.cca.2019.02.005_bb0075","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archneur.65.10.noc80013","article-title":"Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B","volume":"65","author":"Leinonen","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archneurol.2010.357","article-title":"In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults","volume":"68","author":"Sojkova","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/archneurol.2011.153","article-title":"Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology","volume":"68","author":"Wolk","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cca.2019.02.005_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.22068","article-title":"18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial","volume":"68","author":"Vandenberghe","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2006.09.014","article-title":"CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment","volume":"251","author":"Stefani","year":"2006","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.cca.2019.02.005_bb0105","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3233\/JAD-160766","article-title":"Memory correlates of Alzheimer's disease cerebrospinal Fluid markers: a longitudinal cohort study","volume":"60","author":"Reijs","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2019.02.005_bb0110","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00221-018-5210-x","article-title":"Multiplex immunoassay measurement of amyloid-\u03b242 to amyloid-\u03b240 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease","volume":"236","author":"Vogelgsang","year":"2018","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.cca.2019.02.005_bb0115","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3233\/JAD-160398","article-title":"Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-\u03b2 peptides in human cerebrospinal fluid and application to a clinical cohort","volume":"54","author":"Klafki","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2019.02.005_bb0120","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuint.2008.12.016","article-title":"[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients","volume":"54","author":"Svedberg","year":"2009","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.cca.2019.02.005_bb0125","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","article-title":"PET imaging of amyloid deposition in patients with mild cognitive impairment","volume":"29","author":"Forsberg","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2019.02.005_bb0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","article-title":"Amyloid biomarkers in Alzheimer's disease","volume":"36","author":"Blennow","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.cca.2019.02.005_bb0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","article-title":"Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b2 42 in humans","volume":"59","author":"Fagan","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0140","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42: a cross-validation study against amyloid positron emission tomography","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0145","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Alzheimer's disease neuroimaging initiative, comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0150","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.dadm.2015.09.001","article-title":"Revolutionizing Alzheimer's disease and clinical trials through biomarkers","volume":"1","author":"Mattsson","year":"2015","journal-title":"Alzheimer's Dement. (Amst., Neth.)"},{"key":"10.1016\/j.cca.2019.02.005_bb0155","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2019.02.005_bb0160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/jnc.13838","article-title":"Reference measurement procedure for CSF amyloid beta (A\u03b2)1-42 and the CSF A\u03b21-42\/A\u03b21-40 ratio - a cross-validation study against amyloid PET","volume":"139","author":"Pannee","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2019.02.005_bb0165","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer's disease","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2019.02.005_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fnins.2015.00345","article-title":"The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events","volume":"9","author":"Blennow","year":"2015","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.cca.2019.02.005_bb0180","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/brain\/awu367","article-title":"Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer's disease","volume":"138","author":"Mattsson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.cca.2019.02.005_bb0185","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.cca.2019.02.005_bb0190","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.cca.2019.02.005_bb0195","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","article-title":"Imaging beta-amyloid burden in aging and dementia","volume":"68","author":"Rowe","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2019.02.005_bb0200","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/mp.2010.17","article-title":"Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress","volume":"15","author":"Manolopoulos","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.cca.2019.02.005_bb0205","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","article-title":"Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline","volume":"283","author":"N\u00e4slund","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2019.02.005_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/01.wnl.0000191298.68045.50","article-title":"Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease","volume":"66","author":"Prohovnik","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2019.02.005_bb0215","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13195-018-0418-3","article-title":"Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.cca.2019.02.005_bb0220","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0225","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1212\/01.wnl.0000267428.62582.aa","article-title":"CSF tau\/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study","volume":"69","author":"Li","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2019.02.005_bb0230","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000008156","article-title":"Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients","volume":"43","author":"Fukuyama","year":"2000","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0235","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archneur.63.7.936","article-title":"Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition","volume":"63","author":"Peskind","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cca.2019.02.005_bb0240","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.neurobiolaging.2007.08.019","article-title":"The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease","volume":"30","author":"Glodzik-Sobanska","year":"2009","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2019.02.005_bb0245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0304-3940(94)90677-7","article-title":"Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease","volume":"172","author":"van Gool","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2019.02.005_bb0250","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/JAD-2001-3306","article-title":"Cerebrospinal fluid Abeta40 and Abeta42: Natural course and clinical usefulness","volume":"3","author":"Shoji","year":"2001","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.cca.2019.02.005_bb0255","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","article-title":"Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle","volume":"326","author":"Kang","year":"2009","journal-title":"Science"},{"issue":"Suppl. 2","key":"10.1016\/j.cca.2019.02.005_bb0260","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1526-4637.2011.01125.x","article-title":"Provider detailing: an intervention to decrease prescription opioid deaths in Utah","volume":"12","author":"Cochella","year":"2011","journal-title":"Pain Med."},{"key":"10.1016\/j.cca.2019.02.005_bb0265","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000048642","article-title":"Decreased CSF-\u03b2-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of \u03b2-amyloid induced by disparate mechanisms","volume":"13","author":"Sj\u00f6gren","year":"2002","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.cca.2019.02.005_bb0270","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.54.5.1099","article-title":"Decreased -amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"54","author":"Otto","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2019.02.005_bb0275","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1212\/01.WNL.0000128091.92139.0F","article-title":"Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease","volume":"62","author":"Tiraboschi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2019.02.005_bb0280","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0896-6273(95)90079-9","article-title":"Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain","volume":"15","author":"Naslund","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.cca.2019.02.005_bb0285","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0304-3940(92)90444-C","article-title":"Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid","volume":"135","author":"Wisniewski","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cca.2019.02.005_bb0290","unstructured":"G. Deuschl, W. Maier, S3-Leitlinie \u201cDemenzen\u201d, http:\/\/www.dgn.org\/leitlinien, posted 25 Januar 2016, Accessed 29 November 2017, Deuschl G, Maier W S3-Leitlin. Demenzen. Dtsch. Gesellschaft F\u00fcr Neurol. Hrsg. Leitlinien F\u00fcr Diagnostik Und Ther. Der Ne1urol. (n.d.). http:\/\/tinyurl.com\/hkwk6lf (accessed November 29, 2017)."},{"key":"10.1016\/j.cca.2019.02.005_bb0295","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1093\/hmg\/ddq221","article-title":"Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals","volume":"19","author":"Corneveaux","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cca.2019.02.005_bb0300","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/hmg\/ddm031","article-title":"Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants","volume":"16","author":"Grupe","year":"2007","journal-title":"Hum. Mol. Genet."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119300579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119300579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T18:00:34Z","timestamp":1606413634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119300579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":60,"alternative-id":["S0009898119300579"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.02.005","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison between amyloid-PET and CSF amyloid-\u03b2 biomarkers in a clinical cohort with memory deficits","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}